Abstract library

451 results for "octreotide test (OT)".
#305 Risk Stratification Using Octreotide Test for Patients with Gastroenteropancreatic Neuroendocrine Tumors: Results of Prospective Validation of the Test
Introduction: We recently demonstrated that a plasma CgA decrement >30% after octreotide s.c. injection is a simple criterion for treatment with Somatostatin analogues (SSA) of gastroenteropancreatic endocrine tumors.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Sara Massironi
#354 Risk Stratification Using Octreotide Test For Patients With Gastro-Entero-Pancreatic Neuroendocrine Tumors: Results Of Prospective Validation Of The Test
Introduction: Criteria for treatment with somatostatin analogs (SSAs) of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are presence of somatostatin receptors, a positive Octreoscan® or hormonal decrement >50% after octreotide s.c. injection (octreotide test, OT). We demonstrated that a plasma CgA decrement >/=30% after OT is a selection criterion able to predict the clinical response to SSAs.
Conference:
Category: Basic
Presenting Author: Dr Roberta Elisa Rossi
#1910 Acute Somatostatin Analog Suppression Test in a Patient with Thyrotropin-secreting Pituitary Macroadenoma
Introduction: Thyrotropin-secreting pituitary adenomas are rare and often plurihormonal tumours. The long-acting somatostatin analogues (SSA) are effective in cases not cured after surgery.
Conference: 14th Annual ENETS conference (2017)
Category: Clinical cases/reports
Presenting Author: MD, PhD Raluca Trifanescu
#2081 Preclinical Testing of SSA Compounds in a Model of Pancreatic Neuroendocrine Tumors to Optimize Scheduling and Drug Exposition
Introduction: Somatostatin analogues (SSA) such as Octreotide and Lanreotide have demonstrated a significant benefit in Neuroendocrine Tumors, particularly in the well/moderately differentiated types. Nevertheless, there are still several aspects of SSA treatments that remain unsolved, such as drug exposition in patients and schedule optimization.
Conference: 15th Annual ENETS conference (2018)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: PhD Oriol Casanovas
#11 Plasma chromogranin - A response to octreotide test: Prognostic value for clinical outcome in endocrine digestive tumors
Introduction: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) expressing somatostatin receptors may be treated with somatostatin analogues (SSAs). Selection criteria are a positive Octreoscan® or a >50% hormone level decrease after octreotide s.c. injection (octreotide test) (OT). Plasma chromogranin A (CgA) is the best general GEP-NET marker, but data on CgA response to OT are scant.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: MD, PhD Sara Massironi
#34 Plasma Chromogranin A(CgA) and Urinary 5 Hydroxy-indoleacetic acid(5-HIAA) use in monitoring somatostatin analogue(SSA) therapy at Newcastle NHS Foundation Trust
Introduction: Two main biochemical markers, plasma chromogranin A (CgA) and urinary 5 hydroxy-indoleacetic acid (5-HIAA) are used to aid staging and monitoring of patients with neuroendocrine (NET) tumors. Somatostatin analogues (SSA) such as octreotide and lanreotide have been used to alleviate symptoms and disease progression in NET patients. This study evaluates the use of CgA and 5HIAA in monitoring NET patients on SSA therapy at Newcastle NHS Foundation Trust.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Andy James
Authors: Teo L, Hearn K, Bernstone G, Wright R, ...
#12 Chromogranin A as a predictor of progression, regression or stable disease in ileo-cecal (midgut) carcinoid tumors
Introduction: A general characteristic for NETs is their expression of certain proteins, such as chromogranin A (CgA), which is released from the dense core vesicles of NE cells, occasionally together with cell specific hormones, such as gastrin and serotonin. Plasma CgA seems to be closely related to tumor burden of intestinal carcinoid tumors in humans.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Kenneth Jensen
#924 Somatostatin Analogs (SSA) in Patients with Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia: A Case Series
Introduction: Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) is a rare lung disease associated with proliferation of neuroendocrine cells in the lung. Although typically considered a benign condition, DIPNECH causes chronic, progressive cough and dyspnea. There have been no treatments described in the literature.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Dr. Jonathan R Strosberg
#1074 Usefulness of a Combination of a 48-Hour Fasting and a Glucagon Tolerance Test
Introduction: The 72-hour fasting test is the gold standard for the diagnosis of insulinoma. However, the test can become a burden for both patients and medical staff and, shortening the duration of fast has been attempted. There are several reports on the high sensitivity of fasting test but only a few reports on its specificity. An insulinoma can be localized using invasive tests such as endoscopic ultrasonography and selective arterial secretagogue injection test. Therefore, insulinoma detection with high specificity may be needed to avoid unnecessary examinations.
Conference: 12th Annual ENETS Conference (2015)
Category: ...none of the below
Presenting Author: Keijiro Ueda
Authors: Ueda K, Lee L, Hijioka M, Igarashi H, ...
#1505 A Blood-Based Multi-Transcript Test, the NETest, Predicts and Defines PRRT Efficacy in Neuroendocrine Tumors
Introduction: Peptide receptor radionuclide therapy (PRRT) is an effective NET treatment. Predicting response is based on somatostatin receptor expression and efficacy evaluated by RECIST criteria. Both have limited accuracy. The NETest measures tumor activity in blood and correlates cell signaling and metabolism directly with tumor activity.
Conference: 13th Annual ENETS conference (2016)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Professor Mark Kidd
Authors: Bodei L, Kidd M, Severi S, Drozdov I, ...
Keywords: NETest, PRRT